---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001145"
form_type: "8-K"
ticker: "USNA"
cik: "0000896264"
company_name: "USANA HEALTH SCIENCES INC"
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:47:40.131326+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# USANA Q2 net sales $238M (-10% YoY), EPS $0.89; FY2023 guidance raised at low end

## Summary
- Q2 net sales $238M, down 10% YoY; diluted EPS $0.89 vs $1.00.
- Active customers 487k, down 13% YoY; sequential rise in mainland China customers (+5%).
- FY2023 guidance: net sales $900-950M (prev $875-950M), EPS $2.65-3.30 (prev $2.40-3.30).
- Greater China net sales $129M, +4% sequential; mainland China local-currency sales +10% QoQ.
- Plans to open 25th market, India, in late 2023; first new market since 2018.

## SEC filing metadata
- accession: 0001157523-23-001145
- form_type: 8-K
- ticker: USNA
- cik: 0000896264
- company_name: USANA HEALTH SCIENCES INC
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/0001157523-23-001145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/a53479151.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001145
- JSON: https://secwatch.observer/filing/0001157523-23-001145.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001145.txt

## Key facts
- Earnings Releases
  USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $900 to $950 million, EPS $2.65 to $3.30. Guidance raised.
  - Period: fiscal year 2023
  - Revenue: $900 to $950 million
  - EPS: $2.65 to $3.30
  - Guidance: raised
  - Result: guidance update
  source text: Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/0001157523-23-001145-index.htm
- Earnings Releases
  USANA HEALTH SCIENCES INC reported second quarter ended July 1, 2023 results: revenue $238 million, EPS $0.89.
  - Period: second quarter ended July 1, 2023
  - Revenue: $238 million
  - EPS: $0.89
  - Result: reported results
  source text: Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323001145/0001157523-23-001145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.